Detailing the Promising Clinical Outcomes from Phase 2 Trial of VTX2735 in Cryopyrin-Associated Periodic Syndromes (CAPS)

Time: 8:00 am
day: Day 1


  • Exploring the clinical validation of VTX2735 in CAPS with topline phase 2 data showing an 85% mean reduction in Key Symptom Score, affirming VTX2735’s potential as a peripheral NLRP3 inhibitor for CAPS treatment
  • Exploring VTX2735’s potential in cardiovascular diseases, with a focus on MACE prevention and recurrent pericarditis an opportunity to address unmet medical needs